AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 3126527
Drug: R 58
RxNorm normalized name: dextromethorphan HBr 58 MG / guaifenesin 1000 MG 12 HR Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R 58 735 (5 mg b.i.d. for 2 days followed by 10 mg b.i.d. for 5 days)
Trial: 25555191
Drug: 50% dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50% dose of verteporfin (PDT)
Trial: 25555191
Drug: 30% dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30% dose of verteporfin (PDT)
Trial: 24004887
Drug: Calcium supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplementation (1500 mg Ca/d)
Trial: 7180065
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid (1.5 g)
Trial: 9039270
Drug: SP plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SP plus daily iron (SPD)
Trial: 8115073
Drug: Oral iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral iron therapy
Trial: 7657848
Drug: Isradipine (1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isradipine (1.25 mg twice daily)
Trial: 8466728
Drug: Methyldopa (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methyldopa (250 mg twice daily)
Trial: 8466728
Drug: Isradipine +
RxNorm normalized name: Isradipine
DrugBank: Isradipine (DB00270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isradipine + Captopril (25 mg or 50 mg once daily for non-responders)
Trial: 8466728
Drug: Methyldopa +
RxNorm normalized name: Methyldopa
DrugBank: Methyldopa (DB00968)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methyldopa + Captopril (25 mg or 50 mg once daily for non-responders)
Trial: 8466728
Drug: Placebo +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo + Captopril (25 mg or 50 mg once daily for non-responders)
Trial: 26859648
Drug: Phytic combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phytic combination peels
Trial: 20731529
Drug: ATOR 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATOR 20 mg up-titrated to 80 mg
Trial: 20731529
Drug: ROSU 10
RxNorm normalized name: sulfacetamide
DrugBank: Sulfacetamide (DB00634)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ROSU 10 mg up-titrated to 40 mg
Trial: 8206564
Drug: Hydrochlorothiazide with
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide with oral potassium
Trial: 8206564
Drug: Hydrochlorothiazide with
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide with oral potassium and magnesium
Trial: 24727483
Drug: Extended, nontailored
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended, nontailored treatments (12 weeks of counseling, nicotine replacement, and bupropion)
Trial: 15998356
Drug: Placebo twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo twice daily for 3 months
Trial: 1823041
Drug: Nd-YAG laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nd-YAG laser treatment
Trial: 2844549
Drug: Ketotifen 1
RxNorm normalized name: ketotifen 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketotifen 1 mg b.i.d. for one month
Trial: 11420579
Drug: Continuous Positive
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous Positive Airway Pressure (CPAP) plus standard medical therapy for CHF
Trial: 11420579
Drug: Standard medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard medical therapy for CHF
Trial: 15248223
Drug: Etanercept (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept (25 mg, twice weekly, subcutaneous injection)
Trial: 9638413
Drug: Multimodality therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodality therapy combining pancreatic resection with neo‐ and adjuvant locoregional targeting immunochemotherapy (Group A)
Trial: 2492234
Drug: Leuprolide, 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leuprolide, 1 mg subcutaneously per day, administered from the midluteal phase before IVF treatment
Trial: 4855496
Drug: Orotic acid
RxNorm normalized name: Orotic acid
DrugBank: Orotic acid (DB02262)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orotic acid (100 mg/kg/day) orally in 2 daily doses from 1st to 5th day of life
Trial: 27943522
Drug: TAP block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAP block with 40 ml of 0.25% bupivacaine
Trial: 27943522
Drug: Wound infiltration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wound infiltration with 40 ml of 0.25% bupivacaine
Trial: 25378135
Drug: Intravenous firocoxib
RxNorm normalized name: Firocoxib
DrugBank: Firocoxib (DB09217)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous firocoxib (57 mg)
Trial: 25378135
Drug: Oral paste
RxNorm normalized name: Oral Paste
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral paste firocoxib (57 mg)
Trial: 3519879
Drug: no therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: no therapy until relapse, then treatment with BCP
Trial: 30099128
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment response for NE
Trial: 30099128
Drug: Response to
RxNorm normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Response to LUTS treatment
Trial: 22758791
Drug: Protamine zinc
RxNorm normalized name: Protamine zinc insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protamine zinc recombinant human insulin (PZIR) at 0.3 U/kg
Trial: 22758791
Drug: Protamine zinc
RxNorm normalized name: Protamine zinc insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protamine zinc recombinant human insulin (PZIR) at 0.8 U/kg at three separate sites
Trial: 19074911
Drug: Abatacept (approximately
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abatacept (approximately 10 mg/kg)
Trial: 9888410
Drug: OTZ (70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OTZ (70 mg/kg IV every 8 hours for 9 days)
Trial: 1981319
Drug: Prazosin (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prazosin (0.25 mg i.v.)
Trial: 19464535
Drug: Intradermal (i.d.)
RxNorm normalized name: IOBENGUANE I 123
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal (i.d.) vaccination with 3.0 microg HA
Trial: 19464535
Drug: Intradermal (i.d.)
RxNorm normalized name: IOBENGUANE I 123
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal (i.d.) vaccination with 6.0 microg HA
Trial: 19464535
Drug: Intramuscular (i.m.)
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular (i.m.) vaccination with 15.0 microg HA
Trial: 19464535
Drug: Intradermal (i.d.)
RxNorm normalized name: IOBENGUANE I 123
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal (i.d.) vaccination
Trial: 19464535
Drug: Intramuscular (i.m.)
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular (i.m.) vaccination
Trial: 7957006
Drug: Soybean oil
RxNorm normalized name: Soybean Oil
DrugBank: Soybean oil (DB09422)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soybean oil plus psyllium fibre (20 g/day)
Trial: 7957006
Drug: Coconut oil
RxNorm normalized name: Coconut Oil
DrugBank: Coconut oil (DB14322)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coconut oil plus psyllium fibre (20 g/day)
Trial: 1728438
Drug: Captopril (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (50 mg p.o.)
Trial: 2122618
Drug: Chemoembolization (CHE)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemoembolization (CHE) as initial therapy
Trial: 2122618
Drug: Chemoembolization (CHE)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemoembolization (CHE) with additional portal vein chemotherapy
Trial: 49561
Drug: Oral sucrose
RxNorm normalized name: TootSweet 24% Oral Sucrose Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral sucrose plus electrolytes as a maintenance solution
Trial: 49561
Drug: Oral sucrose
RxNorm normalized name: TootSweet 24% Oral Sucrose Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral sucrose plus electrolytes
Trial: 49561
Drug: Oral glucose‐electrolyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral glucose‐electrolyte solutions
Trial: 19851433
Drug: Dextrose tablet
RxNorm normalized name: Dextrose
DrugBank: Dextrose, unspecified form (DB09341)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextrose tablet (6 g)
Trial: 19851433
Drug: Buccal glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buccal glucose spray (10 doses, 0.84 g of glucose)
Trial: 16830288
Drug: Ranitidine bismuth
RxNorm normalized name: RANITIDINE BISMUTH CITRATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine bismuth citrate 2x400 mg, metronidazole 3x500 mg, and tetracycline 2x1000 mg for 14 days (RMT group)
Trial: 16830288
Drug: Pantoprazole 2x40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pantoprazole 2x40 mg, bismuth subcitrate 4x300 mg, amoxicillin 2x1000 mg, and clarithromycin 2x500 mg for 14 days (PBAC group)
Trial: 11378663
Drug: OMC (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OMC (40 mg omeprazole once a day, 500 mg metronidazole and 250 mg clarithromycin twice daily for 7 days)
Trial: 11378663
Drug: NA (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NA (300 mg nizatidine once a day and 1000 mg amoxicillin twice daily for 14 days)
Trial: 2887885
Drug: Atenolol (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (10 mg IV every 6 h for 3 days, then 100 mg orally daily for 4 days)
Trial: 30841030
Drug: Propofol 3
RxNorm normalized name: fospropofol 35 mg/mL intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 3 mg/kg over 3 min
Trial: 25660046
Drug: Control solution
RxNorm normalized name: Nausea Control Solution
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control solution (saline)
Trial: 23238118
Drug: Multidisciplinary rehabilitation
RxNorm normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multidisciplinary rehabilitation program (twice‐weekly training for 12 weeks starting 1 month after hospital discharge)
Trial: 10473925
Drug: Cefepime (2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefepime (2.0 g q. 8 h)
Trial: 8935482
Drug: Oral sumatriptan
RxNorm normalized name: Sumatriptan
DrugBank: Sumatriptan (DB00669)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral sumatriptan 100 mg (first dose)
Trial: 8935482
Drug: Oral sumatriptan
RxNorm normalized name: Sumatriptan
DrugBank: Sumatriptan (DB00669)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral sumatriptan 100 mg (second dose)
Trial: 23238499
Drug: inactive nasal
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: inactive nasal spray + calcium 500 mg
Trial: 20404307
Drug: Canakinumab (anti-interleukin-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canakinumab (anti-interleukin-1 therapy)
Trial: 4902494
Drug: Control solution
RxNorm normalized name: Nausea Control Solution
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control solution
Trial: 111945
Drug: 25 g
RxNorm normalized name: AndroGel 1.25 g Packets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 g of glucose
Trial: 365312
Drug: Oral 5-fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral 5-fluorouracil (5-FU)
Trial: 365312
Drug: Oral Methyl
RxNorm normalized name: methylal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Methyl CCNU
Trial: 31566030
Drug: Pantoprazole 40
RxNorm normalized name: pantoprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pantoprazole 40 mg once daily for 5 days
Trial: 12607793
Drug: Lansoprazole 15
RxNorm normalized name: lansoprazole 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 15 mg once daily for 5 days
Trial: 31566030
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg once daily for 5 days
Trial: 30879775
Drug: Cavit G
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cavit G (3M ESPE)
Trial: 28244907
Drug: Intravenous tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous tranexamic acid (1 g bolus)
Trial: 28244907
Drug: Oral tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral tranexamic acid (1.95 g orally 2 hours preoperatively)
Trial: 25823907
Drug: 2-week buprenorphine
RxNorm normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 2-week buprenorphine taper
Trial: 21323599
Drug: High-normal target
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-normal target TSH (2.0-4.0 mIU/L)
Trial: 17934662
Drug: Glimepiride 4
RxNorm normalized name: glimepiride 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glimepiride 4 mg (Amaryl)
Trial: 15525713
Drug: Intradermal injection
RxNorm normalized name: Dryvax Intradermal Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal injection of trivalent inactivated influenza vaccine (6 mug of hemagglutinin per antigen)
Trial: 15525713
Drug: Intramuscular injection
RxNorm normalized name: rabies, intramuscular injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection of standard dose of trivalent inactivated influenza vaccine (15 mug of hemagglutinin per antigen)
Trial: 7574735
Drug: Plachitin (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plachitin (300 mg, 100 mg as CDDP) - Group A
Trial: 7574735
Drug: Plachitin particles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plachitin particles (300 mg) - Group B
Trial: 7574735
Drug: CDDP (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CDDP (100 mg) - Group C
Trial: 2114208
Drug: Topically applied
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topically applied cromolyn solution
Trial: 31602695
Drug: Crocus sativus
RxNorm normalized name: CROCUS SATIVUS WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crocus sativus capsules (30 mg daily, 15 mg twice/day)
Trial: 31602695
Drug: Placebo capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules (twice/day)
Trial: 31602695
Drug: Crocus sativus
RxNorm normalized name: CROCUS SATIVUS WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crocus sativus capsules
Trial: 28156154
Drug: Insulin timing
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin timing intervention (injected or infused 30 minutes before the meal to 15 minutes after the meal)
Trial: 28156154
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (standard insulin timing)
Trial: 28156154
Drug: Insulin timing
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin timing intervention (for volunteers with baseline A1C in the upper half)
Trial: 12939313
Drug: Adrenomedullin co-infused
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adrenomedullin co-infused with N(G)‐monomethyl‐L‐arginine (3 mg/kg bolus and 30 micro g/(kg. min) continuous intravenous infusion)
Trial: 6997374
Drug: Revaccination with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Revaccination with ACI vaccine
Trial: 6997374
Drug: ACI vaccine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACI vaccine, 'Vaxgrip', and 'Mutagripe'
Trial: 30037208
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (1 g IV before induction, followed by 1 g IV infusion at 8-hour intervals for 48 hours)
Trial: 17372174
Drug: Oral deferiprone
RxNorm normalized name: Deferiprone
DrugBank: Deferiprone (DB08826)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral deferiprone 75 mg/kg per day (combined group)
Trial: 9709942
Drug: 16 mg/day
RxNorm normalized name: futibatinib 16 mg/day (4 mg x 4) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16 mg/day DHT gel
Trial: 9709942
Drug: 32 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 32 mg/day DHT gel
Trial: 7930274
Drug: Fixed dose
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed dose subcutaneous heparin (12,500 U every 12 h delayed until 4 h after the end of streptokinase therapy)
Trial: 3259071
Drug: Various treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various treatments
Trial: 29243341
Drug: 2% carteolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% carteolol hydrochloride drops administered to the lesion surface twice daily for 6 months
Trial: 27306192
Drug: Ziprasidone augmentation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ziprasidone augmentation
Trial: 20923712
Drug: Cerebrolysin (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cerebrolysin (30 mL)
Trial: 17953718
Drug: Febuxostat 120
RxNorm normalized name: Febuxostat 120 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Febuxostat 120 mg (single dosing)
Trial: 16586149
Drug: Red wine
RxNorm normalized name: Red wine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Red wine (0.35 mg hydroxytyrosol)
Trial: 16586149
Drug: Olive oil
RxNorm normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olive oil (1.7 mg hydroxytyrosol)
Trial: 17258718
Drug: Rofecoxib 25
RxNorm normalized name: rofecoxib 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rofecoxib 25 mg/day
Trial: 3906673
Drug: Baclofen (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baclofen (25 to 60 mg per day)
Trial: 3906673
Drug: Diazepam (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (10 to 40 mg per day)
Trial: 27442674
Drug: Dexmedetomidine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (1 μg/kg loading before anesthesia induction and 0.3 μg/kg/h infusion during surgery)
Trial: 21069596
Drug: Music therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music therapy (MT) treatment with three cycles of 12 active sessions each, three times a week for one month, followed by one month of no treatment
Trial: 17706003
Drug: Aripiprazole (starting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aripiprazole (starting dose 15 mg/day, adjusted 10-30 mg/day)
Trial: 9563219
Drug: Propranolol (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (60 mg twice daily for seven days)
Trial: 8129128
Drug: Alfentanil 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfentanil 0.2 mg
Trial: 12930014
Drug: Hydrogen peroxide
RxNorm normalized name: Hydrogen Peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrogen peroxide vaginal douching (20 ml of 3% hydrogen peroxide)
Trial: 8846276
Drug: 25 G
RxNorm normalized name: AndroGel 1.25 g Packets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 G Quincke needle
Trial: 8846276
Drug: 29 G
RxNorm normalized name: Publix Pen Needle 29 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 29 G Quincke needle
Trial: 16650261
Drug: Inhaled nitrous
RxNorm normalized name: nitrous oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nitrous oxide (50% N2O/50% O2)
Trial: 8828672
Drug: Autologous erythrocyte
RxNorm normalized name: erythrocytes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous erythrocyte infusion (700-ml infusion, 42% hematocrit)
Trial: 1385599
Drug: New combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New combination and selection of items reflecting different facets of depression
Trial: 31074816
Drug: Vitamin B6
RxNorm normalized name: vitamin B6
DrugBank: Pyridoxine (DB00165)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin B6 intake ≥35 mg/d
Trial: 31074816
Drug: Vitamin B12
RxNorm normalized name: Vitamin B12
DrugBank: Cyanocobalamin Co-57 (DB09385)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin B12 intake ≥30 μg/d
Trial: 7489435
Drug: Ketorolac 0.5
RxNorm normalized name: KETOROLAC 0.5/PHENYLEPHRINE2.5/PROPARACAINE0.5/TROPICAMIDE 1%OPH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac 0.5 mg/kg
Trial: 8193492
Drug: Pethidine 1
RxNorm normalized name: Pethidine
DrugBank: Meperidine (DB00454)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pethidine 1 mg/kg
Trial: 24350872
Drug: Intensive anti-hypertensive
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive anti-hypertensive therapy with a systolic target of <140 mmHg within one hour
Trial: 24350872
Drug: Standard guideline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard guideline recommended treatment of <180 mmHg
Trial: 24350872
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (Intensive and Standard treatment)
Trial: 15927285
Drug: Early abciximab
RxNorm normalized name: Abciximab
DrugBank: Abciximab (DB00054)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early abciximab administration (27 patients)
Trial: 15927285
Drug: Late abciximab
RxNorm normalized name: Abciximab
DrugBank: Abciximab (DB00054)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Late abciximab administration (28 patients)